- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07762469
Diagnostic Performance of a Flexible Penile Monitoring System for ED
Diagnostic Performance Evaluation and Clinical Translation Research of a New Intelligent Flexible Penile Monitoring System for Erectile Dysfunction
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Nocturnal Penile Tumescence (NPT) monitoring is essential for differentiating psychogenic from organic ED. However, traditional mechanical devices pose physical loads that may trigger arousals during REM sleep. This study introduces a flexible sensing technology with an ultra-thin (<0.8mm) layer to achieve "unfelt" monitoring.
The primary objective is to assess the consistency of physical parameters (peak rigidity % and tumescence) between the flexible system and RigiScan Plus. Participants will be randomized 1:1 into two sequences for a two-night crossover monitoring process with a 3-7 day washout period. Secondary objectives include evaluating clinical diagnosis agreement (Kappa), sleep quality metrics (Arousal frequency), and patient comfort scores (VAS). Additionally, the study will explore the correlation between "deformation heatmaps" and hemodynamic indicators from Penile Color Doppler Ultrasound (CDDU) to improve fine-grained ED subtyping.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studiecontact
- Naam: Chao Sun
- Telefoonnummer: +86 13813966939
- E-mail: fertility@126.com
Studie Locaties
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210009
- Zhongda Hospital Southeast University
-
Contact:
- Chao Sun
- Telefoonnummer: +86-13813966939
- E-mail: fertility@126.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Males aged 18-70 years with good communication and compliance.
- Able to follow clinical Standard Operating Procedures (SOPs) and complete two-stage nocturnal monitoring and clinic-induced tests.
- Fully informed about the study and signed the informed consent form.
- For ED Group: Clinically diagnosed with erectile dysfunction with an IIEF-5 score < 21.
- For Healthy Group: Normal erectile function, no history of related physiological diseases or sexual psychological disorders, with an IIEF-5 score ≥ 21.
Exclusion Criteria:
- Systemic diseases: Severe cardiovascular disease (e.g., recent myocardial infarction, unstable angina), uncontrolled severe diabetes, or severe obstructive sleep apnea syndrome.
- Local anatomical factors: Severe penile malformation, spinal cord injury, or organic structural damage caused by pelvic fracture; or major surgery within the last six months.
- Skin and allergy factors: Active infection or eczema in the penile area, or known allergy to flexible materials (medical-grade silicone/adhesives).
- Mental and psychological factors: Untreated or unstable severe depression, anxiety, or other mental disorders.
- Medication interference: Current use of PDE5 inhibitors, androgens, anti-androgens, or drugs that significantly interfere with REM sleep structure.
- Other factors: Currently participating in other interventional clinical trials, or judged by researchers to have poor compliance.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
ED Patient Group
Males aged 18-70 years diagnosed with erectile dysfunction (ED) for more than 6 months, with an IIEF-5 score of less than 21.
|
A novel, ultra-thin (<0.8mm) flexible sensing system used for prospective monitoring of penile rigidity and tumescence during sleep.
RigiScan Plus
|
|
Healthy Volunteer Group
Healthy male volunteers aged 18-70 years with normal erectile function and an IIEF-5 score of 21 or greater.
|
A novel, ultra-thin (<0.8mm) flexible sensing system used for prospective monitoring of penile rigidity and tumescence during sleep.
RigiScan Plus
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Measurement Accuracy of Peak Rigidity
Tijdsspanne: Day 1 and Day 8
|
Mean bias and 95% limits of agreement for peak rigidity (%) between the novel flexible system and RigiScan Plus.
|
Day 1 and Day 8
|
|
Measurement Accuracy of Maximum Girth Expansion
Tijdsspanne: Day 1 and Day 8
|
Mean bias and 95% limits of agreement for maximum girth expansion (cm) between the novel flexible system and RigiScan Plus.
|
Day 1 and Day 8
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Diagnosis Agreement Rate
Tijdsspanne: Day 1 and Day 8
|
The degree of agreement in diagnostic conclusions (normal, psychogenic, or organic ED) between the two systems, evaluated using Cohen's Kappa coefficient.
|
Day 1 and Day 8
|
|
Sleep Efficiency
Tijdsspanne: Day 1 and Day 8
|
Sleep efficiency, defined as the percentage of total sleep time spent asleep out of the total time spent in bed (%), collected by a medical-grade sleep recorder.
|
Day 1 and Day 8
|
|
REM Sleep Percentage
Tijdsspanne: Day 1 and Day 8
|
Percentage of total sleep time spent in the Rapid Eye Movement (REM) sleep stage (%), measured by a medical-grade sleep recorder.
|
Day 1 and Day 8
|
|
Unintended Arousal Frequency
Tijdsspanne: Day 1 and Day 8
|
Frequency of unintended arousals (number of events per hour) during sleep, measured by a medical-grade sleep recorder.
|
Day 1 and Day 8
|
|
Subjective Sleep Perception Score (PSQI)
Tijdsspanne: Day 2 and Day 8
|
Participant subjective sleep perception evaluated using the Pittsburgh Sleep Quality Index (PSQI).
The score ranges from 0 to 21, where higher scores indicate worse sleep quality.
|
Day 2 and Day 8
|
|
Subjective Wearing Comfort Score
Tijdsspanne: Day 2 and Day 8
|
Participant subjective wearing comfort evaluated using the Visual Analogue Scale (VAS).
The scale ranges from 0 (extreme discomfort) to 10 (maximum comfort), where higher scores indicate better comfort
|
Day 2 and Day 8
|
|
Participant Scheme Preference
Tijdsspanne: Day 8
|
Number of participants who express a final preference for the flexible monitoring system versus RigiScan Plus.
|
Day 8
|
|
Response Latency During AVSS
Tijdsspanne: Day 1
|
The response latency, defined as the time delay in seconds from the onset of Audiovisual Sexual Stimulation (AVSS) to a penile rigidity increase of more than 10%.
|
Day 1
|
|
Congestion Initiation Slope During AVSS
Tijdsspanne: Day 1
|
Congestion initiation slope (rigidity change rate, % per second) reflected by deformation heatmaps during the Audiovisual Sexual Stimulation (AVSS) test.
|
Day 1
|
|
Correlation with Vascular Subtyping Characteristics
Tijdsspanne: Within 1 week after monitoring.
|
Correlation analysis between morphology feature vectors from deformation heatmaps and hemodynamic parameters measured by Penile Color Doppler Ultrasound (CDDU).
|
Within 1 week after monitoring.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie stoel: Bin Xu, Zhongda hospital
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2026ZDSYLL244-P01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .